AstraZeneca (AZN) Tops Q4 EPS by 10c
Get Alerts AZN Hot Sheet
Join SI Premium – FREE
AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.58, $0.10 better than the analyst estimate of $1.48. Revenue for the quarter came in at $6.42 billion versus the consensus estimate of $6.32 billion.
GUIDANCE:
AstraZeneca sees FY2019 EPS of $3.50-$3.70.
- Product Sales: A high single-digit percentage increase
For earnings history and earnings-related data on AstraZeneca (AZN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Impinj (PI) Tops Q1 EPS by 11c, provides guidance
- Universal Health Realty (UHT) Reports Q1 EPS of $0.38
- SLM (SLM) Tops Q1 EPS by 20c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!